Efficacy and Prescription Considerations for Switching from Basal Insulin and Incretins to Insulin Degludec/Liraglutide

DOI

Bibliographic Information

Other Title
  • 基礎インスリンとインクレチン製剤の併用からIDegLiraへ切り替えた場合の有効性と処方上の注意点

Search this article

Description

<p>We evaluated that the effect of HbA1c improvement and clinical factors on HbA1c change in patients who had switched from basal insulin and Dulaglutide (Group A) or DPP-4 inhibitor (Group B) to insulin Degludec/Liraglutide (IDegLira) for more than six months. In group A, 23 patients had taken 15.0±5.1 doses and showed no significant change in HbA1c, while in group B, 24 patients had taken 15.0±7.0 doses and shown a reduction in HbA1c from 9.0 % to 8.1 % (p<0.01). In group B, the decrease in HbA1c was significantly greater in patients whose baseline HbA1c and C-peptide immunoreactivity/plasma glucose×100 had been high. Furthermore, the smaller the amount of basal insulin before switching, the smaller the decrease in HbA1c tended to be, and HbA1c remained unchanged or worsened in all cases with <10 units of basal insulin. We herein discuss and report the prescribing considerations when switching from basal insulin and incretin combination to IDegLira.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top